drugset / Trial / NCT06909006
Semaglutide Treatment in Type 1 Diabetes
Phase 3
Not yet recruiting
122 enrolled
Nordsjaellands Hospital
Aarhus University Hospital · collabSteno Diabetes Center Copenhagen · collabSteno Diabetes Center Odense · collabZealand University Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.
Timeline
- Start
- 2025-10
- Primary completion
- 2028-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Semaglutide | Peptide | 2.4 mg | Subcutaneous |